INCORPORATING PATIENT PREFERENCES INTO THE VALUE ASSESSMENT OF NOVEL LUNG CANCER DRUGS: EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT
Author(s)
Qinwen Xu, Ph.D. candidate1, Chenghui Li, MS2, Jinsong Geng, PhD, MD3.
1Evidence-based Medicine Center, Medical School of Nantong University; Nursing Department, Nantong First People's Hospital, Nantong, China, 2Nantong University, Nantong, China, 3Evidence-based Medicine Center, Medical School of Nantong University, Nantong, China.
1Evidence-based Medicine Center, Medical School of Nantong University; Nursing Department, Nantong First People's Hospital, Nantong, China, 2Nantong University, Nantong, China, 3Evidence-based Medicine Center, Medical School of Nantong University, Nantong, China.
OBJECTIVES: To develop a multidimensional value assessment framework for novel lung cancer drugs and quantify patient preferences using a discrete choice experiment to inform reimbursement, pricing, and value-based decision-making.
METHODS: A value assessment framework for novel lung cancer drugs was first developed through a literature review to identify relevant treatment attributes and levels.A discrete choice experiment (DCE) was conducted to quantify patient preferences for key value attributes of novel lung cancer drugs. The DCE questionnaire was developed based on relevant treatment attributes, including overall survival (OS), health-related quality of life (HRQoL), and treatment cost. Panel choice data were collected and analyzed using a mixed logit model to estimate preference parameters and explore heterogeneity in patient choices. In addition, willingness to pay (WTP) for incremental improvements in OS and HRQoL was calculated, and the marginal WTP per quality-adjusted life year (QALY) was further estimated.
RESULTS: The value assessment framework identified survival, quality of life, and cost as the core attributes for evaluating novel lung cancer drugs.Both prolonged OS and improved HRQoL had significant positive effects on patients’ treatment choices, whereas higher cost had a significant negative effect. Patient preferences also showed a certain degree of heterogeneity. Relative importance analysis indicated that cost and survival benefit contributed similarly to decision-making, accounting for 44.00% and 43.79%, respectively. The estimated monthly WTP was CNY 431.25 for each additional month of OS and CNY 601.08 for each 0.1-unit improvement in HRQoL. The corresponding marginal WTP was CNY 78,869.84 per QALY.
CONCLUSIONS: The DCE approach effectively captured lung cancer patients' preference structures and trade-offs among survival, quality of life, and treatment cost. These findings provide quantitative evidence to support patient-centered value assessment of novel lung cancer drugs and may inform reimbursement negotiation and health insurance decision-making.
METHODS: A value assessment framework for novel lung cancer drugs was first developed through a literature review to identify relevant treatment attributes and levels.A discrete choice experiment (DCE) was conducted to quantify patient preferences for key value attributes of novel lung cancer drugs. The DCE questionnaire was developed based on relevant treatment attributes, including overall survival (OS), health-related quality of life (HRQoL), and treatment cost. Panel choice data were collected and analyzed using a mixed logit model to estimate preference parameters and explore heterogeneity in patient choices. In addition, willingness to pay (WTP) for incremental improvements in OS and HRQoL was calculated, and the marginal WTP per quality-adjusted life year (QALY) was further estimated.
RESULTS: The value assessment framework identified survival, quality of life, and cost as the core attributes for evaluating novel lung cancer drugs.Both prolonged OS and improved HRQoL had significant positive effects on patients’ treatment choices, whereas higher cost had a significant negative effect. Patient preferences also showed a certain degree of heterogeneity. Relative importance analysis indicated that cost and survival benefit contributed similarly to decision-making, accounting for 44.00% and 43.79%, respectively. The estimated monthly WTP was CNY 431.25 for each additional month of OS and CNY 601.08 for each 0.1-unit improvement in HRQoL. The corresponding marginal WTP was CNY 78,869.84 per QALY.
CONCLUSIONS: The DCE approach effectively captured lung cancer patients' preference structures and trade-offs among survival, quality of life, and treatment cost. These findings provide quantitative evidence to support patient-centered value assessment of novel lung cancer drugs and may inform reimbursement negotiation and health insurance decision-making.
Conference/Value in Health Info
2026-09, ISPOR Asia Pacific 2026, Bangkok, Thailand
Value in Health, Volume 55, Issue S1
Code
HTA18
Topic
Health Technology Assessment
Topic Subcategory
Decision & Deliberative Processes, Value Frameworks & Dossier Format
Disease
SDC: Oncology, SDC: Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)